Clinical Trial Update: A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma [Phase 2]

View source ↗

Summary

Phase 2 trial update for Anlotinib in recurrent high-grade glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: First People's Hospital of Hangzhou | Conditions: Recurrent High-grade Glioma | Phase 2 | Status: UNKNOWN